AIM: Long-chain acylcarnitines have been postulated to be sensitive biomarkers of acetaminophen (APAP)-induced hepatotoxicity in mouse models. In the following study, the relationship of acylcarnitines with other known indicators of APAP toxicity was examined in children receiving low-dose (therapeutic) and high-dose ('overdose' or toxic ingestion) exposure to APAP. MATERIALS & METHODS: The study included three subject groups: group A (therapeutic dose, n = 187); group B (healthy controls, n = 23); and group C (overdose, n = 62). Demographic, clinical and laboratory data were collected for each subject. Serum samples were used for measurement of APAP protein adducts, a biomarker of the oxidative metabolism of APAP and for targeted metabolomics analysis of serum acylcarnitines using ultra performance liquid chromatography-triple-quadrupole mass spectrometry. RESULTS: Significant increases in oleoyl- and palmitoyl-carnitines were observed with APAP exposure (low dose and overdose) compared with controls. Significant increases in serum ALT, APAP protein adducts and acylcarnitines were observed in overdose children that received delayed treatment (time to treatment from overdose >24 h) with the antidote N-acetylcysteine. Time to peak APAP protein adducts in serum was shorter than that of the acylcarnitines and serum ALT. CONCLUSION: Perturbations in long-chain acylcarnitines in children with APAP toxicity suggest that mitochrondrial injury and associated impairment in the β-oxidation of fatty acids are clinically relevant as biomarkers of APAP toxicity.
AIM: Long-chain acylcarnitines have been postulated to be sensitive biomarkers of acetaminophen (APAP)-induced hepatotoxicity in mouse models. In the following study, the relationship of acylcarnitines with other known indicators of APAPtoxicity was examined in children receiving low-dose (therapeutic) and high-dose ('overdose' or toxic ingestion) exposure to APAP. MATERIALS & METHODS: The study included three subject groups: group A (therapeutic dose, n = 187); group B (healthy controls, n = 23); and group C (overdose, n = 62). Demographic, clinical and laboratory data were collected for each subject. Serum samples were used for measurement of APAP protein adducts, a biomarker of the oxidative metabolism of APAP and for targeted metabolomics analysis of serum acylcarnitines using ultra performance liquid chromatography-triple-quadrupole mass spectrometry. RESULTS: Significant increases in oleoyl- and palmitoyl-carnitines were observed with APAP exposure (low dose and overdose) compared with controls. Significant increases in serum ALT, APAP protein adducts and acylcarnitines were observed in overdosechildren that received delayed treatment (time to treatment from overdose >24 h) with the antidote N-acetylcysteine. Time to peak APAP protein adducts in serum was shorter than that of the acylcarnitines and serum ALT. CONCLUSION: Perturbations in long-chain acylcarnitines in children with APAPtoxicity suggest that mitochrondrial injury and associated impairment in the β-oxidation of fatty acids are clinically relevant as biomarkers of APAPtoxicity.
Authors: Hartmut Jaeschke; Gregory J Gores; Arthur I Cederbaum; Jack A Hinson; Dominique Pessayre; John J Lemasters Journal: Toxicol Sci Date: 2002-02 Impact factor: 4.849
Authors: Kenneth L Muldrew; Laura P James; Leslie Coop; Sandra S McCullough; Howard P Hendrickson; Jack A Hinson; Philip R Mayeux Journal: Drug Metab Dispos Date: 2002-04 Impact factor: 3.922
Authors: Anne M Larson; Julie Polson; Robert J Fontana; Timothy J Davern; Ezmina Lalani; Linda S Hynan; Joan S Reisch; Frank V Schiødt; George Ostapowicz; A Obaid Shakil; William M Lee Journal: Hepatology Date: 2005-12 Impact factor: 17.425
Authors: Timothy J Davern; Laura P James; Jack A Hinson; Julie Polson; Anne M Larson; Robert J Fontana; Ezmina Lalani; Santiago Munoz; A Obaid Shakil; William M Lee Journal: Gastroenterology Date: 2006-03 Impact factor: 22.682
Authors: Karsten Suhre; Christa Meisinger; Angela Döring; Elisabeth Altmaier; Petra Belcredi; Christian Gieger; David Chang; Michael V Milburn; Walter E Gall; Klaus M Weinberger; Hans-Werner Mewes; Martin Hrabé de Angelis; H-Erich Wichmann; Florian Kronenberg; Jerzy Adamski; Thomas Illig Journal: PLoS One Date: 2010-11-11 Impact factor: 3.240
Authors: L P James; E V Capparelli; P M Simpson; L Letzig; D Roberts; J A Hinson; G L Kearns; J L Blumer; J E Sullivan Journal: Clin Pharmacol Ther Date: 2008-10-15 Impact factor: 6.875
Authors: Angela B Reid; Richard C Kurten; Sandra S McCullough; Robert W Brock; Jack A Hinson Journal: J Pharmacol Exp Ther Date: 2004-10-01 Impact factor: 4.030
Authors: Laura P James; Lynda Letzig; Pippa M Simpson; Edmund Capparelli; Dean W Roberts; Jack A Hinson; Timothy J Davern; William M Lee Journal: Drug Metab Dispos Date: 2009-05-13 Impact factor: 3.922
Authors: Dean W Roberts; William M Lee; Jack A Hinson; Shasha Bai; Christopher J Swearingen; R Todd Stravitz; Adrian Reuben; Lynda Letzig; Pippa M Simpson; Jody Rule; Robert J Fontana; Daniel Ganger; K Rajender Reddy; Iris Liou; Oren Fix; Laura P James Journal: Clin Gastroenterol Hepatol Date: 2016-09-15 Impact factor: 11.382
Authors: Andrew J Lutkewitte; George G Schweitzer; Stefanie Kennon-McGill; Melissa M Clemens; Laura P James; Hartmut Jaeschke; Brian N Finck; Mitchell R McGill Journal: Food Chem Toxicol Date: 2018-03-11 Impact factor: 6.023